Introduction

Persistent atrial fibrillation (AF) and hypertension (high blood pressure) are two interconnected cardiovascular diseases that have a major influence on world health. Atrial Fibrillation is a type of arrhythmia where the heart beats irregularly and often too fast, whereas hypertension is characterised by blood pressure that rises above or equal to 140 mmHg (systolic) and 90 mmHg (diastolic). Hypertension is the most common modifiable risk factor for AF, affecting more than 30% of individuals globally. In turn, persistent AF is linked to a higher risk of heart failure, stroke, and cardiovascular death. Through structural and electrical remodelling of the heart, hypertension encourages the development of AF, while AF worsens organ damage associated with hypertension. Therefore, it is crucial to effectively regulate blood pressure in patients with established arrhythmias to both avoid the occurrence of AF and mitigate its progression.^1,2,3 

According to studies, people with hypertension are 73% more likely to develop AF than people with normal blood pressure (BP). Additionally, more than 70% of AF patients also have hypertension, highlighting the close connection between the two disorders. Public health statistics show a dose-response relationship: even within pre-hypertensive ranges (120–139/80–89 mmHg), the chance of developing AF increases by 18% for every 20 mmHg increase in systolic blood pressure (SBP).^2,3,4 

The relation between hypertension and persistent atrial fibrillation

Increased blood pressure causes the left atrium of the heart to dilate, and it stimulates the renin-angiotensin-aldosterone system (RAAS), which in turn causes collagen deposition, fibroblast growth, and interstitial fibrosis. Hypertension-induced mechanical stress also modifies gap junction function and calcium handling, which further disrupts the rhythm of the atria of the heart. The atria eventually become pro-arrhythmic due to these changes. Even modest increases in blood pressure (>120/80 mmHg) can increase the chance of AF. Moreover, different studies indicate that for every 10 mmHg increase in SBP, the incidence of AF increases by 90%.^4,5,6

Hemodynamic instability during AF and abnormal ventricular rates are also caused by hypertension. When coordinated atrial contraction is lost, ventricular filling is compromised, which lowers cardiac output, especially in individuals who already have diastolic dysfunction or hypertensive left ventricular hypertrophy. Persistent tachycardia linked to AF can potentially result in tachycardia-induced cardiomyopathy, which exacerbates the symptoms of heart failure.^7,8 

The risk of thromboembolic events, including stroke, is greatly increased when hypertension and AF coexist. A hypercoagulable state is exacerbated by endothelial dysfunction and widespread inflammation, both of which are encouraged by hypertension. In addition to reducing atrial blood flow, left atrial enlargement and scarring raise the risk of clot development. According to research, individuals who have both AF and hypertension are significantly more likely to suffer a stroke than those who have just one of the conditions. Therefore, maintaining good blood pressure control is crucial for both halting the progression of AF and reducing the risk of stroke in those who are affected.^7,8,9 

Blood pressure control strategies

Persistent AF is made much worse by hypertension, which increases the risk of arrhythmias and encourages atrial remodelling. This cycle must be broken by effective blood pressure (BP) control, which calls for a mix of lifestyle changes and focused pharmaceutical treatments.⁹

Renin-angiotensin aldosterone system (RAAS)

RAAS inhibitors, such as Angiotensin-converting enzyme (ACE) inhibitors and Angiotensin receptor blockers (ARBs), mitigate the structural remodelling caused by hypertension, hence lowering the risk of AF. ARBs have a better safety profile than ACE inhibitors, with fewer risks of angioedema, coughing, and gastrointestinal bleeding. Calcium channel blockers (CCBs) and beta-blockers are good at controlling the ventricular rate in AF.^10,11 

Diuretics for volume overload

For the treatment of volume overload in hypertensive AF patients with heart failure, loop diuretics (such as furosemide) continue to be essential. The lowest effective dose is used to sustain normal fluid balance because overuse can cause renal failure. They can be used in some cases with RAAS inhibitors to improve blood pressure regulation.

Non-pharmacological approaches

Lifestyle changes that address major risk factors and enhance cardiovascular health are the mainstay of non-pharmacological strategies for controlling hypertension. Enhancing circulation and oxygen delivery with regular exercise, such as 30 minutes of brisk walking per day, is helpful to decrease blood pressure, which improves cardiac fitness and lowers the incidence of AF.^12,13 

Consuming less salt and more fruits, vegetables, and whole grains, all of which have been demonstrated to dramatically lower BP. Additionally, following the DASH or Mediterranean style diet can help to support heart health. Losing weight is especially beneficial for lowering the burden of AF; research shows that a 10% decrease in body weight can cut the risk of recurrent episodes in half.^12,13,14

Atrial stretch and oxidative stress are decreased when sleep apnea is managed with procedures such as continuous positive airway pressure (CPAP) therapy, which enhances rhythm stability. Yoga, mindfulness, and acupuncture are stress-reduction methods that can assist in reducing overactivity of the nervous system, which is a typical cause of AF episodes. By lowering stress on the heart and enhancing general cardiovascular health, such as reducing alcohol consumption and quitting smoking, one can lower the risk of arrhythmia. To lessen the effect of hypertension on persistent AF, these non-pharmacological techniques are helpful adjuncts to pharmacological treatment.^14,15

Benefits of blood pressure control in persistent atrial fibrillation

Blood pressure (BP) management reverses pathological remodelling and improves atrial integrity by reducing atrial stretch and scarring, which lowers the risk of arrhythmia recurrence. Another important advantage of BP treatment for patients with chronic AF is better rhythm control. Atrial stiffness and electrical properties are two major factors that contribute to the burden of AF, and they decrease when BP is lowered. For example, it has been demonstrated that RAAS inhibitors lower the risk of AF by reducing inflammation and fibrosis.^16,17,18

Challenges and considerations in blood pressure management 

Managing hypertension in patients with persistent AF involves several challenges. For example, determining the optimal BP, minimising the risk of hypotension (low blood pressure) as side effects, and ensuring that patients are continuously monitored and adhere to their treatment plans. Targeting blood pressure on an individual basis is crucial, since significant lowering can result in consequences. There is evidence to support that maintaining SBP within the normal range reduces cardiovascular risks, lessens the burden of AF, and diminishes atrial remodelling. But low blood pressure (SBP < 120 mmHg) can worsen heart failure or coronary artery disease by affecting blood flow. To achieve safe and effective blood pressure control, individualised treatment strategies based on cardiovascular risk profiles and comorbidities are essential.¹⁹

Successful BP treatment in AF patients depends on patient adherence and ongoing monitoring. Real-time feedback on the effectiveness of treatment is provided by ambulatory blood pressure monitoring, which is especially helpful in identifying nighttime BP rises and any hidden hypertension. But adherence is still a problem; less than one-third of hypertension patients regularly take their medications as directed. Nurse-driven treatment approaches, patient education, and digital health tools can maximise results and increase adherence rates. Reducing cardiovascular morbidity and preventing worsening arrhythmia in AF patients requires addressing these issues holistically.²⁰ 

Summary

The development of persistent AF is greatly accelerated by hypertension, and the prevention of increasing arrhythmia and its related consequences depends on efficient BP management. Atrial remodelling is fueled by elevated BP and prolongs AF. Atrial stretch is decreased, rhythm stability is enhanced, and the risk of stroke and cardiovascular events is decreased when SBP is kept between 120 and 130 mmHg. Atrial scarring can be successfully reduced by pharmacological treatments, while non-pharmacological approaches, including salt restriction, weight loss, and sleep apnea management, also improve blood pressure control. An integrated approach that incorporates medication, lifestyle modifications, and patient education is crucial for managing both hypertension and atrial fibrillation. By adopting a holistic approach, clinicians can more successfully delay the progression of AF and cardiovascular morbidity.